Aardvark Therapeutics, Inc. earnings releases AARD

Annual Quarterly

Aardvark Therapeutics, Inc. last reported quarterly results on Aug 11, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $0 and diluted EPS of -$0.66. It usually reports 37–44 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 12, 2026.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 37–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released Quarter Revenue Net income Diluted EPS
Aug 11, 2026
42 days after quarter end
Q2 FY2026
ended Jun 30, 2026
0
-14
-0.1%
-0.66
+0.0%
May 7, 2026
37 days after quarter end
Q1 FY2026
ended Mar 31, 2026
0
-22
-131.9%
-0.99
-39.4%
Nov 13, 2025
44 days after quarter end
Q3 FY2025
ended Sep 30, 2025
0
-16
-0.75
Aug 13, 2025
44 days after quarter end
Q2 FY2025
ended Jun 30, 2025
0
-14
-0.66
May 14, 2025
44 days after quarter end
Q1 FY2025
ended Mar 31, 2025
0
-9
-0.71

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
AARD (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Diego, CA
SEC filer status
, Emerging growth company
SEC CIK
1774857

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.